HQL-79

Cat. No.: HY-108259

CAS No.: 162641-16-9

Molecular Formula: $C_{22}H_{27}N_5O$

Molecular Weight: 377.48

Target: PGE synthase

Pathway: Immunology/Inflammation

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 2 mg/mL (5.30 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6491 mL	13.2457 mL	26.4915 mL
	5 mM	0.5298 mL	2.6491 mL	5.2983 mL
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

HQL-79, a potent, selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, highly selectively inhibits the synthesis of PGD_2, and acts as an anti-allergic agent, with a K_d of 0.8 μM and an IC_{50} of 6 μM. Shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS[1].

IC_{50} & Target

IC50: 6 μM (H-PGDS)[1]
Kd: 0.8 μM (H-PGDS)[1]

In Vitro

HQL-79 is a competitive inhibitor against substrate PGH2 and a non-competitive one against GSH[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Aritake K, et al. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem. 2006

Jun 2;281(22):15277-86. Epub 2006 Mar 17.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA